Accurately measuring and modeling Th2 and Th17 endotypes in severe asthma

Annals of Translational Medicine

Volumn 5, Issue 4, 2017, Pages

  Hart, Kevin M ^a   Choy, David F ^b   Bradding, Peter ^c   Wynn, Thomas A ^a   Arron, Joseph R ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN 3; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; NITRIC OXIDE;

ASTHMA; CYTOKINE PRODUCTION; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; HOUSE DUST ALLERGY; HUMAN; LETTER; NEUTROPHIL COUNT; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; SPUTUM; TH17 CELL; TH2 CELL;

EID: 85014370057     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.02.07     Document Type: Letter

References (27)

1. Choy DF, Hart KM, Borthwick LA, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015;7:301ra129.
2. Arron JR, Choy DF, Laviolette M, et al. Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. Eur Respir J 2014;43:627-9.
3. Shikotra A, Choy DF, Ohri CM, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 2012;129:104-11.e1-9.
4. Vrugt B, Wilson S, Underwood J, et al. Mucosal inflammation in severe glucocorticoid-dependent asthma. Eur Respir J 1999;13:1245-52.
5. Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 1996;154:224-30.
6. Siddiqui S, Mistry V, Doe C, et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol 2008;122:335-41, 341.e1-3.
7. Bradley BL, Azzawi M, Jacobson M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991;88:661-74.
8. Chen F, Wu W, Millman A, et al. Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion. Nat Immunol 2014;15:938-46.
9. Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest 2016;126:3279-95.
10. Staton TL, Choy DF, Arron JR. Biomarkers in the clinical development of asthma therapies. Biomark Med 2016;10:165-76.
11. Roche HL. A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma. Available online: https://clinicaltrials.gov/ct2/show/NCT02099656
12. Sanofi. Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma (EXPEDITION). Available online: https://clinicaltrials.gov/ct2/show/NCT02573233
13. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-9.
14. Chandriani S, DePianto DJ, N'Diaye EN, et al. Endogenously expressed IL-13Ra2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol 2014;193:111-9.
15. Badalyan V, Thompson R, Addo K, et al. TNF-a/IL-17 synergy inhibits IL-13 bioactivity via IL-13Ra2 induction. J Allergy Clin Immunol 2014;134:975-8.e5.
16. Irvin C, Zafar I, Good J, et al. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. J Allergy Clin Immunol 2014;134:1175-1186.e7.
17. Liu W, Liu S, Verma M, et al. Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. J Allergy Clin Immunol 2016. [Epub ahead of print].
18. Arron JR, Choy DF, Scheerens H, et al. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013;10 Suppl:S206-13.
19. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011;50:215-27.
20. Fingleton J, Braithwaite I, Travers J, et al. Serum periostin in obstructive airways disease. Eur Respir J 2016;47:1383-91.
21. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
22. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med 2014;29:388-94.
23. Vannella KM, Ramalingam TR, Borthwick LA, et al. Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis. Sci Transl Med 2016;8:337ra65.
24. Raundhal M, Morse C, Khare A, et al. High IFN-? and low SLPI mark severe asthma in mice and humans. J Clin Invest 2015;125:3037-50.
25. Christianson CA, Goplen NP, Zafar I, et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J Allergy Clin Immunol 2015;136:59-68.e14.
26. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016;4:781-96.
27. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013;188:1294-302.c